Clinical outcomes of carbapenem vs. non-carbapenem therapy in hospitalized adults with shigellosis.
Publication Title
Antimicrob Steward Healthc Epidemiol
Document Type
Article
Publication Date
1-1-2026
Keywords
oregon; portland; psvmc; ppmc
Abstract
BACKGROUND: Management of shigellosis is increasingly complicated by antimicrobial resistance, yet susceptibility testing is rarely performed, and the role of broad-spectrum empiric therapy in hospitalized adults remains unclear.
METHODS: We conducted a multi-center retrospective cohort study of adults hospitalized with stool-confirmed
RESULTS: Of 45 patients included in the outcome analyses, 29 (64%) received carbapenems and 16 (36%) received non-carbapenem antibiotics. Median time from antibiotic initiation to symptom resolution was 18 hours (IQR 9-37) in the carbapenem group and 29 hours (IQR 15-36) in the non-carbapenem group, with no significant difference between groups (
CONCLUSIONS: Carbapenem use was not associated with faster symptom resolution and was associated with significantly longer hospitalization. Susceptibility testing was underutilized and may be essential to guide local empiric and targeted therapy decisions.
Area of Special Interest
Digestive Health
Specialty/Research Institute
Infectious Diseases
Specialty/Research Institute
Pharmacy
Specialty/Research Institute
Epidemiology
DOI
10.1017/ash.2026.10820
